ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2335

Antiendothelial Cell Antibodies in Juvenile Dermatomyositis: A Proteomics-Based Approach

Rie Karasawa1, Mayumi Tamaki1, Toshiko Sato1, Megumi Tanaka1, Kazuo Yudoh1 and James Jarvis2, 1Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, 2Department of Genetics, Genomics & Bioinformatics, University at Buffalo, Buffalo, NY

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoantibodies, autoantigens, juvenile dermatomyositis and proteomics

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Pediatric Rheumatology – Pathogenesis and Genetics Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic disorder of childhood characterized by muscle inflammation and vasculopathy. The mechanisms of the blood vessel injury in JDM remain to be fully solved. Anti-endothelial cell antibodies (AECA) are detected in infectious, inflammatory diseases and autoimmune diseases such as vasculitis, and we have hypothesized that such antibodies may target the endothelium in JDM. In this study, we aimed to comprehensively detect endothelial target antigens in JDM using a proteomics approach. Methods: We extracted proteins from human aortic endothelial cells (HAEC), which were used as antigen sources. To comprehensively detect target antigens for AECA, we separated proteins extracted from HAEC by two-dimensional electrophoresis (2DE) and then transferred them onto membranes. Using standard western blotting techniques, membranes were probed with sera from children with JDM or healthy controls. Autoantigens that were positive only in sera from children with JDM but not healthy controls were then identified by mass spectrometry (MS). Enzyme-linked immunosorbent assay (ELISA) was then used to confirm presence of specific antibodies. Results: Five candidate protein spots as JDM-specific proteins were detected in 2DE-WB. From these spots, we successfully identified 34 proteins. 22 of the 34 identified antigens represented membrane proteins. Using Ingenuity Pathway Analysis, 27 of the 34 candidate target antigens for AECA in JDM were predicted to interact with chaperone proteins involved in antigen processing and presentation. Among the 8 chaperone or co-chaperone proteins were heat shock cognate 71 kDa protein (HSC70), heat shock protein HSP 90-beta (HS90B) and stress-induced-phosphoprotein 1 (STIP1), a protein that mediates the association of HSC70 and HSP90. By ELISA, IgG autoantibodies to HSC70 were detected in 23% of the patients with JDM (n=39). However, 50% of the untreated JDM patients with active disease (n=10) had anti-HSC70 antibodies, in contrast to 7% (p<0.05) of the patients with juvenile idiopathic arthritis (JIA) (n=15) and 5% (p<0.01) of control children (n=20). 13% of the treated JDM patients with active disease (n=15) and 14% of the inactive patients with JDM (n=14) had anti-HSC70 antibodies. IgG autoantibodies to HS90B were detected in 6% of the patients with JDM (n=31) and in 5% of control children, in contrast to 20% of the patients with JIA. Similarly, IgG autoantibodies to STIP1 were not detected patients with JDM, but were present in 5% of control children and 20% of the patients with JIA. Conclusion: IgG antibodies to chaperone proteins in the proteome of HAEC are present in the sera of children with JDM. The presence of AECA in JDM could implicate these antibodies in the disorders of immune system in JDM.


Disclosure: R. Karasawa, None; M. Tamaki, None; T. Sato, None; M. Tanaka, None; K. Yudoh, None; J. Jarvis, None.

To cite this abstract in AMA style:

Karasawa R, Tamaki M, Sato T, Tanaka M, Yudoh K, Jarvis J. Antiendothelial Cell Antibodies in Juvenile Dermatomyositis: A Proteomics-Based Approach [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/antiendothelial-cell-antibodies-in-juvenile-dermatomyositis-a-proteomics-based-approach/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antiendothelial-cell-antibodies-in-juvenile-dermatomyositis-a-proteomics-based-approach/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology